Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Former CEO pleads...

    Former CEO pleads guilty to fentanyl spray kickback scheme

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-01-10T09:00:05+05:30  |  Updated On 10 Jan 2019 9:00 AM IST
    Former CEO pleads guilty to fentanyl spray kickback scheme

    BOSTON - The former chief executive of a company that produces a potentially addictive fentanyl spray pleaded guilty Wednesday to scheming with his colleagues to bribe doctors into increasing prescriptions to boost sales.


    Former Insys Therapeutics CEO Michael Babich also agreed to cooperate with federal prosecutors who are preparing to go to trial in Boston later this month against the Chandler, Arizona-based company's wealthy co-founder, John Kapoor, and other executives.


    Prosecutors say Kapoor, Babich and others conspired to pay kickbacks to doctors in the form of speaking fees to get them to prescribe the powerful opioid painkiller to more people and in higher doses while the opioid epidemic raged.


    The speaking events were billed as opportunities for other doctors to learn about the drug but were "often poorly attended and merely used as an excuse for participants and his or her friends to have a free meal and drinks paid for by Insys," Assistant U.S. Attorney Fred Wyshak told the judge.


    Prosecutors say Insys executives also bribed doctors by moving their office's employees onto the Insys payroll and hiring their friends or relatives. Several doctors have already been convicted of accepting kickbacks in exchange for prescribing the drug meant for cancer patients, often to people who didn't need it.


    Babich, 42, is the latest Insys executive to agree to cooperate with prosecutors in the hopes of getting a lesser sentence. Former sales executive Alec Burlakoff pleaded guilty in November and is also expected to testify at the trial, which begins Jan. 28 and is expected to last several months.


    An attorney for Babich declined to comment after the hearing, citing a gag order the judge has imposed on both sides in the case.


    An email was sent Wednesday to an attorney for Kapoor. His previous lawyer said Kapoor looks forward to fighting the charges and believes he will be vindicated.


    Also Read: Indian-origin chemist jailed for the illegal sale of drugs in the UK

    Alec BurlakoffbribecancerCEOfentanyl sprayFred WyshakGuiltyInsys TherapeuticsJohn KapoorkickbackMichael Babichopioid painkiller
    Source : AP

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok